ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
1 . A pharmaceutical composition comprising a compound of formula II or a pharmaceutically acceptable salt thereof:
wherein
R 1 is hydroxy, alkoxy, haloalkyl, or halo;
R 2 is hydroxy or alkoxy;
R 3 is alkyl, halo, or haloalkyl;
R 4 , R 5 , and R 6 are independently hydrogen, hydroxy, alkoxy, halo, haloalkyl, or alkyl; and
R 7 is alkyl or hydrogen.
2 . The composition of claim 1 , wherein R 1 is hydroxy or methoxy.
3 . The composition of any of claims 1 - 2 , wherein R 2 is hydroxy.
4 . The composition of any of claims 1 - 3 , wherein R 3 is methyl,
5 . The composition of any of claims 1 - 4 , wherein R 7 is methyl.
6 . A pharmaceutical composition comprising a compound of formula IV or a pharmaceutically acceptable salt thereof:
wherein
R 8 is hydrogen.
7 . The composition of any of claims 1 - 6 , wherein the composition further comprises an anti-cancer agent selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, epirubicin, cyclophosphamide, capecitabine, 5-fluorouracil, vinorelbine, trastuzumab or bevacizumab.
8 . The composition of any of claims 1 - 7 , wherein the composition further comprises a cyclodextrin.
9 . A kit comprising a composition of any of claims 1 - 8 and a sealable, plastic infusion bag.
10 . The composition of any one of claims 1 - 8 for use in inducing apoptosis in a cancer cell.
11 . The composition of any one of claims 1 - 8 for use in the treatment of cancer in an individual in need of cancer therapy.
12 . The composition of any one of claims 1 - 8 for use in increasing, inducing, or restoring sensitivity of a cancer cell to a chemotherapeutic agent, anti-cancer agent or radiation therapy.
13 . The composition of claim 12 , wherein the cancer cell has lost sensitivity to a chemotherapeutic agent, anti-cancer agent or radiation therapy.
14 . The composition of any one of claims 10 - 13 , wherein said cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer and cancers of the brain.
15 . The compound of any one of claims 10 - 14 , wherein said cancer is human breast cancer or ovarian cancer.